Gilead Sciences Hits Day High with Strong 3.61% Intraday Surge

Gilead Sciences, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen a notable increase of 3.61% in its stock price on June 11, 2026. The stock reached an intraday high of USD 127.34, reflecting a strong performance relative to the broader market, as the S&P 500 gained only 1.75% on the same day. Despite a challenging week and month, where Gilead's stock declined by 2.56% and 5.73% respectively, its year-to-date performance stands at a modest 2.55%. Over the past year, Gilead has delivered a return of 15.16%, although this is below the S&P 500's 22.78% return. Gilead's financial metrics indicate robust management efficiency, highlighted by a high Return on Capital Employed (ROCE) of 26.79%. The company maintains a low Debt to EBITDA ratio of 1.72, showcasing its strong ability to service debt. Additionally, Gilead has consistently reported positive results over the last four quarters, with operating cash flow reaching USD 10,806 million. With a market capitalization of USD 166,661 million and a P/E ratio of 17.00, Gilead Sciences continues to be a significant entity in its industry, supported by high institutional holdings at 89.9%.